1-17 of 17
Yung-Jue Bang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B183: The WEE1 inhibitor AZD1775 in combination with chemotherapy in Asian patients with advanced solid tumors: a phase Ib study

Yung-Jue Bang, Paul De Souza, Sang-We Kim, Jason Lickliter, Yoichi Naito, Keunchil Park, Sanjeev Kumar, Ganesh M. Mugundu, Hidenori Kato
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B183.
https://doi.org/10.1158/1535-7163.TARG-17-B183
Published: 01 January 2018
View article titled, Abstract B183: The WEE1 inhibitor AZD1775 in combination with chemotherapy in Asian patients with advanced solid tumors: a phase Ib study
Journal Articles

Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition

Mei Hua Jin, Ah-Rong Nam, Ji Eun Park, Ju-Hee Bang, Yung-Jue Bang, Do-Youn Oh
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (6): 1145–1154.
https://doi.org/10.1158/1535-7163.MCT-16-0669
Published: 01 June 2017
View article titled, Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition
Open the PDF for Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition in another window
Includes: Supplementary data
Journal Articles

AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells

Ahrum Min, Seock-Ah Im, Hyemin Jang, Seongyeong Kim, Miso Lee, Debora Keunyoung Kim, Yaewon Yang, Hee-Jun Kim, Kyung-Hun Lee, Jin Won Kim, Tae-Yong Kim, Do-Youn Oh, Jeff Brown, Alan Lau, Mark J. O'Connor, Yung-Jue Bang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (4): 566–577.
https://doi.org/10.1158/1535-7163.MCT-16-0378
Published: 02 April 2017
View article titled, AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells
Open the PDF for AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells in another window
Includes: Supplementary data
Journal Articles

HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib

Michael F. Press, Catherine E. Ellis, Robert C. Gagnon, Tobias J. Grob, Marc Buyse, Ivonne Villalobos, Zhiyong Liang, Shafei Wu, Yung-Jue Bang, Shu-Kui Qin, Hyun Cheol Chung, Jianming Xu, Joon Oh Park, Krzysztof Jeziorski, Karen Afenjar, Yanling Ma, Monica C. Estrada, Douglas M. Robinson, Stefan J. Scherer, Guido Sauter, J. Randolph Hecht, Dennis J. Slamon
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (1): 228–238.
https://doi.org/10.1158/1535-7163.MCT-15-0887
Published: 05 January 2017
View article titled, <em>HER2</em> Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib
Open the PDF for <em>HER2</em> Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib in another window
Includes: Supplementary data
Journal Articles

Src as a Therapeutic Target in Biliary Tract Cancer

Ah-Rong Nam, Ji-Won Kim, Ji Eun Park, Ju-Hee Bang, Mei Hua Jin, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Do-Youn Oh, Yung-Jue Bang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (7): 1515–1524.
https://doi.org/10.1158/1535-7163.MCT-16-0013
Published: 05 July 2016
View article titled, Src as a Therapeutic Target in Biliary Tract Cancer
Open the PDF for Src as a Therapeutic Target in Biliary Tract Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A167: A phase I study of MET TKI SAR125844 in Asian patients (pts) with advanced solid tumors

Kohei Shitara, Do-Youn Oh, Tomoya Yokota, Tae Won Kim, Toshihiko Doi, Satoshi Hamauchi, Jin-Hee Ahn, Corinne Gomez, Marzia Harnois, Yung Jue Bang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A167.
https://doi.org/10.1158/1535-7163.TARG-15-A167
Published: 01 December 2015
View article titled, Abstract A167: A phase I study of MET TKI SAR125844 in Asian patients (pts) with advanced solid tumors
Journal Articles

Abstract C266: Evaluation of Src as a therapeutic target in biliary tract cancer.

Do-Youn Oh, Ah-Rong Nam, Tae Yong Kim, Sae-Won Han, Sang-Hyun Song, Seock-Ah Im, Tae-You Kim, Yung-Jue Bang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C266.
https://doi.org/10.1158/1535-7163.TARG-13-C266
Published: 01 November 2013
View article titled, Abstract C266: Evaluation of Src as a therapeutic target in biliary tract cancer.
Journal Articles

RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib

Ahrum Min, Seock-Ah Im, Young-Kwang Yoon, Sang-Hyun Song, Hyun-Jin Nam, Hyung-Seok Hur, Hwang-Phill Kim, Kyung-Hun Lee, Sae-Won Han, Do-Youn Oh, Tae-You Kim, Mark J. O'Connor, Woo-Ho Kim, Yung-Jue Bang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (6): 865–877.
https://doi.org/10.1158/1535-7163.MCT-12-0950
Published: 09 June 2013
View article titled, RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
Open the PDF for RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib in another window
Includes: Supplementary data
Journal Articles

Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer

Hyun-Jin Nam, Seock-Ah Im, Do-Youn Oh, Paul Elvin, Hwang-Phill Kim, Young-Kwang Yoon, Ahrum Min, Sang-Hyun Song, Sae-Won Han, Tae-You Kim, Yung-Jue Bang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (1): 16–26.
https://doi.org/10.1158/1535-7163.MCT-12-0109
Published: 13 January 2013
View article titled, Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer
Open the PDF for Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer in another window
Includes: Supplementary data
Journal Articles

Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer

Hyun-Jin Nam, Keith A. Ching, Julie Kan, Hwang-Phill Kim, Sae-Won Han, Seock-Ah Im, Tae-You Kim, James G. Christensen, Do-Youn Oh, Yung-Jue Bang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (2): 439–451.
https://doi.org/10.1158/1535-7163.MCT-11-0494
Published: 08 February 2012
View article titled, Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer
Open the PDF for Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B260: Antitumor activity of HM781‐36B, an irreversible pan‐HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer cells

Hyun‐Jin Nam, Hwang‐Phill Kim, Young‐Kwang Yoon, Hyung‐Seok Hur, Maeng‐Sup Kim, Gwan‐Sun Lee, Sae‐Won Han, Do‐Youn Oh, Seock‐Ah Im, Tae‐You Kim, Yung‐Jue Bang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B260.
https://doi.org/10.1158/1535-7163.TARG-09-B260
Published: 10 December 2009
View article titled, Abstract B260: Antitumor activity of HM781‐36B, an irreversible pan‐HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer cells
Journal Articles

Abstract C16: Prospective real‐time analysis of p‐cadherin expression to select patients into a phase I oncology trial

Darren W. Davis, Wen Liu, Iman Jilani, Yujian Zhang, John W. Barlow, Louise M. Miller, Reba Winstanley, Jayesh Desai, Kathy R. Alpaugh, Harry Cooper, Roger B. Cohen, Yung‐Jue Bang, Do‐Youn Oh, Mi‐Yeong Kim, Yoon‐Ju Bae, Athena Countouriotis, David R. Shalinsky, Woo Ho Kim
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C16.
https://doi.org/10.1158/1535-7163.TARG-09-C16
Published: 10 December 2009
View article titled, Abstract C16: Prospective real‐time analysis of p‐cadherin expression to select patients into a phase I oncology trial
Journal Articles

Abstract A252: KRAS mutant lung cancer cells are differentially responsive to MEK inhibition due to AKT or STAT3 activation: Implication for combinatorial approach

Young‐Kwang Yoon, Hwang‐Phill Kim, Sae‐Won Han, Seock‐Ah Im, Do Youn Oh, Yung‐Jue Bang, Tae‐You Kim
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A252.
https://doi.org/10.1158/1535-7163.TARG-09-A252
Published: 10 December 2009
View article titled, Abstract A252: KRAS mutant lung cancer cells are differentially responsive to MEK inhibition due to AKT or STAT3 activation: Implication for combinatorial approach
Journal Articles

Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells

Young-Kwang Yoon, Hwang-Phill Kim, Sae-Won Han, Hyung-Seok Hur, Do Youn Oh, Seock-Ah Im, Yung-Jue Bang, Tae-You Kim
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (9): 2526–2536.
https://doi.org/10.1158/1535-7163.MCT-09-0300
Published: 17 September 2009
View article titled, Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells
Open the PDF for Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells in another window
Includes: Supplementary data
Journal Articles

Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells

Hwang-Phill Kim, Sae-Won Han, Sung-Hak Kim, Seock-Ah Im, Do-Youn Oh, Yung-Jue Bang, Tae-You Kim
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (3): 607–615.
https://doi.org/10.1158/1535-7163.MCT-07-2068
Published: 17 March 2008
View article titled, Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells
Open the PDF for Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells in another window
Journal Articles

Enzastaurin, a protein kinase Cβ inhibitor, suppresses signaling through the Rsk and Bad pathways and induces apoptosis in human gastric cancer cells

Keun-Wook Lee, Sang Gyun Kim, Hwang-Phill Kim, Euna Kwon, Jiran You, Hyung-Jun Choi, Jung-Hyun Park, Byeong-Cheol Kang, Seock-Ah Im, Tae-You Kim, Yung-Jue Bang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B241.
Published: 01 November 2007
View article titled, Enzastaurin, a protein kinase Cβ inhibitor, suppresses signaling through the Rsk and Bad pathways and induces apoptosis in human gastric cancer cells
Journal Articles

Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells

Ju-Hee Lee, Jung-Hyun Park, Yeonjoo Jung, Jee-Hyun Kim, Hyun-Soon Jong, Tae-You Kim, Yung-Jue Bang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (12): 3085–3095.
https://doi.org/10.1158/1535-7163.MCT-06-0419
Published: 15 December 2006
View article titled, Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells
Open the PDF for Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells in another window